While considering the association between metabolic changes in the various brain regions with AD biomarkers (PET, CSF, plasma), it is crucial to consider the spatial and temporal dynamics of amyloid and tau pathologies to understand the underlying mechanisms of AD progression. This evidence concerns the gene MAPT and Alzheimer disease.